|Table of Contents|

The clinical study on PEG-rhG-CSF preventing forneutrophil deficiency of ovarian cancer and cervical cancer chemotherapy

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 02
Page:
279-283
Research Field:
Publishing date:

Info

Title:
The clinical study on PEG-rhG-CSF preventing forneutrophil deficiency of ovarian cancer and cervical cancer chemotherapy
Author(s):
Bi Chunyan; Ren Guoping; Yuan Shexia
Department of Obstetrics and Gynecology,Xinxiang Central Hospital,Henan Xinxiang 453000,China.
Keywords:
pegylated recombinant human granulocyte colony-stimulating factor; ovarian cancer; cervical cancer; chemotherapy; neutrophil deficiency
PACS:
R737.3
DOI:
10.3969/j.issn.1672-4992.2020.02.023
Abstract:
Objective:To explore the effect of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) on neutrophil deficiency in patients with ovarian and cervical cancer chemotherapy and to observe adverse reactions.Methods:136 patients with ovarian and cervical cancer from we April 2015 to June 2017 in this hospitalwere selected and randomly divided into control group (68 cases) and study group (68 cases).The control group was treated with rhG-CSF and the study group was treated with PEG- rhG-CSF,two chemotherapy cycle.Assessed two chemotherapy cycle for the blood absolute neutrophil count (ANC) levels,the incidence and duration of different ANC counts,and adverse events at different times.Results:ANC level of study group at 5 d，7 d,10 d,and 14 d during the first chemotherapy cycle and at 3 d,5 d，7 d,10 d,and 14 d during second chemotherapy cycle were (3.19±0.32)×109/L,(1.93±0.35)×109/L,(2.08±0.39)×109/L,(2.11±0.36)×109/L and (2.79±0.40)×109/L,(2.44±0.33)×109/L,(1.68±0.34)×109/L,(1.71±0.37)×109/L,(1.92±0.34)×109/L respectively,which were higher than the control group,and the difference was statistically significant (P＜0.05).The incidence of ANC<1.5×109/L,ANC<1.0×109/L and ANC<0.5×109/L in the study group during the first and second chemotherapy cycle was 23.53%(16/68),8.82%(6/68),2.94%(2/68) and 29.41%(20/68),10.29%(7/68),5.88%(4/68),lower than the control group,and the difference was statistically significant (P＜0.05).The durations time of ANC<1.5×109/L,ANC<1.0×109/L and ANC<0.5×109/L in the study group during the first andsecond chemotherapy cycle were (3.50±0.18)d,(2.17±0.23)d,(2.06±0.29)d and(4.08±0.22)d,(4.62±0.29)d,(4.11±0.24)d respectively,shorter than the control group,and the difference was statistically significant (P＜0.05).The overall incidence of moderate and severe adverse reactions in the study group was 10.29%(7/68),which was lower than the control group 23.53% (16/68),the difference was statistically significant (P＜0.05).Conclusion:The use of PEG-rhG-CSF can effectively prevent the neutropenia of ovarian cancer and cervical cancer chemotherapy patients,and the adverse reactions are significantly reduced,which is worthy of clinical application.

References:

［1］Xie J,Cao J,Wang JF,et al.Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy:An open-label,randomized,multicenter phase III study［J］.Breast Cancer Research and Treatment,2018,168(2):389-399.
［2］CHENG YF,YU W,WANG YX,et al.Efficacy evaluation and cost-effectiveness analysis of long-short-acting recombinant human granulocyte stimulating factor in the treatment of grade IV myelosuppression［J］.Tumor Prevention & Treatment,2017,30(4):281-284.［程幼夫，余微，王怡鑫，等.长短效重组人粒细胞刺激因子治疗 IV 度骨髓抑制的疗效评价和成本效果分析［J］.肿瘤预防与治疗，2017，30（4）：281-284.］
［3］SONG JL,CHEN MD,AI JZ,et al.Prevention of PEG-rhG-CSF on bone marrow suppression induced by cisplatin-based chemotherapy combined with chemotherapy［J］.The Practical Journal of Cancer,2017,32(10):1725-1727.［宋君利，陈明达，艾建中，等.PEG-rhG-CSF对以顺铂为基础联合化疗所致骨髓抑制的预防作用［J］.实用癌症杂志，2017，32（10）：1725-1727.］
［4］MU J,ZHAO MF,LI YM,et al.Therapeutic effect of PEG-rhG-CSF on neutropenia after treatment of lymphatic malignant tumors［J］.Chinese Journal of Practical Internal Medicine,2017,37(2):150-151.［穆娟，赵明峰，李玉明，等.PEG-rhG-CSF对淋巴系统恶性肿瘤治疗后中性粒细胞减少临床治疗观察［J］.中国实用内科杂志，2017，37（2）：150-151.］
［5］LIU Q,GUAN S,CAO F,et al.Clinical analysis of PEG-rhG-CSF on salvage treatment of neutrophil deficiency in concurrent chemoradiotherapy［J］.Chinese Journal of Cancer Prevention and Treatment,2017,24(7):481-485.［刘青，关嵩，曹峰，等.PEG-rhG-CSF对同步放化疗中性粒细胞缺乏挽救性治疗临床分析［J］.中华肿瘤防治杂志，2017，24（7）：481-485.］
［6］Mohammadian F,Negahdari B.Isolation and characterization of mesenchymal stem cells and its antitumor application on ovarian cancer cell line［J］.Artificial Cells,Nanomedicine,and Biotechnology,2018,46(8):1744-175.
［7］XU SY,DONG LF,JIANG XY,et al.Efficacy and nursing of PEGylated recombinant human granulocyte colony-stimulating factor for prevention and treatment of neutropenia caused by postoperative chemotherapy in breast cancer［J］.Zhonghua Journal of Critical Care Medicine (Electronic Edition),2018,11(3):210-212.［徐淑英，董力枫，蒋晓燕，等.聚乙二醇化重组人粒细胞集落刺激因子防治乳腺癌术后化疗所致中性粒细胞减少的疗效和护理［J］.中华危重症医学杂志（电子版），2018，11（3）：210-212.］
［8］Chinese Society of Clinical Oncology (CSCO),China Anti-lymphoma Alliance (UCLI),China Anti-Cancer Association Breast Cancer Professional Committee,et al.Clinical application of PEG-recombinant human granulocyte stimulating factor (PEG-rhG-CSF) ［J］.Chin J Clinical Oncol,2016,43(7): 271-274.［中国临床肿瘤学会（CSCO），中国抗淋巴瘤联盟（UCLI），中国抗癌协会乳腺癌专业委员会，等.聚乙二醇化重组人粒细胞刺激因子（PEG-rhG-CSF）临床应用中国专家共识［J］.中国肿瘤临床，2016，43（7）：271-274.］
［9］WANG H,LI HP,SONG GH,et al.Effects of prophylactic use of granulocyte colony-stimulating factor on neutropenia induced by adjuvant chemotherapy in breast cancer［J］.Tumour,2016,36(11):1239-1245.［王环，李惠平，宋国红，等.预防性使用粒细胞集落刺激因子对乳腺癌辅助化疗所致中性粒细胞减少的影响［J］.肿瘤，2016，36（11）：1239-1245.］
［10］HUANG Z,YU F,WANG T,et al.Multi-center clinical study of PEG-resistant recombinant human granulocyte stimulating factor for prophylactic neutrophil therapy in patients with osteosarcoma chemotherapy ［J］.Chinese Journal of Bone and Joint,2018,7(9): 693-697.［黄真，鱼锋，王涛，等.聚乙二醇化重组人粒细胞刺激因子对骨肉瘤化疗患者行预防性中性粒细胞治疗的多中心临床研究［J］.中国骨与关节杂志，2018，7（9）：693-697.］
［11］DENG JL,YAO Q,ZHANG YL,et al.Clinical observation of PEGylated recombinant human granulocyte stimulating factor to prevent reduction of neutrophil count after chemotherapy［J］.Journal of Clinical Internal Medicine,2017,34(4):268-270.［邓建良，姚强，张云雷，等.聚乙二醇化重组人粒细胞刺激因子预防化疗后中性粒细胞计数减少的临床观察［J］.临床内科杂志，2017，34（4）：268-270.］
［12］ZHANG W,WANG Y,DING NY,et al.Efficacy and economic analysis of long-and short-acting recombinant human granulocyte stimulating factor on leukopenia in patients with malignant tumors［J］.癌医学,2018,8(5) :811-814.［张伟，王研，丁年羊，等.长、短效重组人粒细胞刺激因子对恶性肿瘤患者白细胞减少症的有效性及经济性分析［J］.肿瘤药学，2018，8（5）：811-814.］
［13］SHAO S,BAI HT,WANG C,et al.Application of polyethylene glycol recombinant human granulocyte colony-stimulating factor in autologous peripheral blood stem cell mobilization in relapsed refractory malignant lymphoma［J］.Chin J Clinical Oncol,2017,44(13):662-666.［邵珊，白海涛，王椿，等.聚乙二醇重组人粒细胞集落刺激因子在复发难治恶性淋巴瘤自体外周血造血干细胞动员中的应用研究［J］.中国肿瘤临床，2017，44（13）：662-666.］
［14］ Kraiem H,Zouari F,Abderrazek RB,et al.Two-Cimensional isoelectric focusing OFFGEL,micro-fluidic lab-on-chip electrophoresis and FTIR for assessment of long-term stability of rhG-CSF formulation［J］.IEEE Transactions on Nanobioscience,2017,16(8):694-702.
［15］ZHANG CY,SHAO J,WU YL,et al.Pharmacokinetics and pharmacodynamics study of PEGylated recombinant human granulocyte colony-stimulating factor injection in healthy volunteers［J］.Drugs & Clinics,2017,32(9):1614-1619.［张春云，邵杰，吴雅丽，等.聚乙二醇化重组人粒细胞集落刺激因子注射液在健康志愿者中的药动学和药效学研究［J］.现代药物与临床，2017，32（9）：1614-1619.］
［16］Beesley VL,Smith DD,Nagle CM,et al.Coping strategies,trajectories,and their associations with patient-reported outcomes among women with ovarian cancer［J］.Supportive Care in Cancer,2018,26(12):4133-4142.
［17］ Behfar M,Faghihi-Kashani S,Hosseini AS,et al.Long-term safety of short-term administration of filgrastim (rhG-CSF) and leukophresis procedure in healthy children: Application of peripheral blood stem cell collection in pediatric donors［J］.Biology of Blood and Marrow Transplantation,2018,24(4):866-870.
［18］CHEN X,SU XQ,YANG LL,et al.The role of PEGylated recombinant human granulocyte stimulating factor in preventing bone marrow suppression after chemotherapy in breast cancer［J］.交通医学,2017,31(4):327-329.［陈希，苏小琴，羊林林，等.聚乙二醇化重组人粒细胞刺激因子在预防乳腺癌化疗后骨髓抑制中的作用［J］.交通医学，2017，31（4）：327-329.］

Memo

Memo:
河南省教育厅自然科学研究计划（编号：2016B3023）
Last Update: 2019-11-29